{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:49:17Z","timestamp":1759366157974,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.arteri.2019.01.005","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T18:04:40Z","timestamp":1554833080000},"page":"278-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tratamiento de la hipercolesterolemia familiar con iPCSK9 en un paciente diagnosticado de distrofia muscular cong\u00e9nita con contraindicaci\u00f3n para la toma de estatinas"],"prefix":"10.1016","volume":"31","author":[{"given":"Sergio","family":"Arnedo Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Daniel","family":"Mosquera Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iratxe","family":"Mart\u00ednez de Narvajas Urra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estela","family":"Men\u00e9ndez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Rabad\u00e1n Pejenaute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Baeza Trinidad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Casa\u00f1as Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"Brea Hernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2019.01.005_bib0045","unstructured":"Rosenson RS, Durrington P. Familial hypercholesterolemia in adults. En: Gordon M Saperia (Ed.), Up to date [consultado 20 Jul 2018]. Disponible en: https:\/\/www.uptodate.com\/contents\/search"},{"key":"10.1016\/j.arteri.2019.01.005_bib0050","unstructured":"Rosenson RS, Ferranti SD, Durrington P. Treatment of drug-resistant Hypercholesterolemia. En: Gordon M Saperia (Ed.), Up to date [consultado 20 Jul 2018]. Disponible en: https:\/\/www.uptodate.com\/contents\/search"},{"key":"10.1016\/j.arteri.2019.01.005_bib0055","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2019.01.005_bib0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jacl.2016.12.004","article-title":"Ef\ufb01cacy and safety of the proprotein convertase subtilisin\/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia","volume":"11","author":"Kastelein","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2019.01.005_bib0070","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: The ODYSSEY ESCAPE trial","volume":"37","author":"Moriarty","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2019.01.005_bib0085","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003294","article-title":"Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia","volume":"5","author":"Wang","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.arteri.2019.01.005_bib0010","unstructured":"Kastelein JJP, Stroes ESG, Stiekema LCA, Rosenson RS. PCSK9 inhibitors: Pharmacology, adverse effects, and use. En: Gordon M Saperia (Ed.), Up to date [consultado 13 Ene 2019]. Disponible en: https:\/\/www.uptodate.com\/contents\/search"},{"key":"10.1016\/j.arteri.2019.01.005_bib0080","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jacl.2017.04.114","article-title":"Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs","volume":"11","author":"Stefanutti","year":"2017","journal-title":"J Clin Lipidol"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021491681930021X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021491681930021X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:31:47Z","timestamp":1759325507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021491681930021X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S021491681930021X"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2019.01.005","relation":{},"ISSN":["0214-9168"],"issn-type":[{"type":"print","value":"0214-9168"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento de la hipercolesterolemia familiar con iPCSK9 en un paciente diagnosticado de distrofia muscular cong\u00e9nita con contraindicaci\u00f3n para la toma de estatinas","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2019.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}